who discovered glp 1 agonists Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions A future Nobel Prize? Looking

Who qualifies for using GLP-1 drugs for weight loss

This article profiles these trials and their implications for management of CVD in people with obesity after briefly tracing the path to the launch of these studies

Liu Y, Jiang X, Chen X

Advantage : Amycretin Development Stage# Amycretin : Phase 1b/2a completed (obesity, Lancet)

Brazil GLP-1 Receptor Agonist Market Trends According to the International Diabetes Federation, approximately 10.6% of the total Brazilian population is currently living with diabetes

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis